Company Filing History:
Years Active: 2011
Title: The Innovative Contributions of Hongmao Sun
Introduction
Hongmao Sun is a notable inventor based in Ramsey, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target oncological disorders. His work is characterized by a commitment to advancing medical treatments through innovative chemical compounds.
Latest Patents
Hongmao Sun holds a patent for "Halo-substituted pyrimidodiazepines." This invention provides PLK1 inhibitor compounds of formula I, which are useful in the treatment or control of cell proliferative disorders, especially oncological disorders. The compounds and formulations containing these compounds may be effective in treating solid tumors, including breast, colon, lung, and prostate tumors, as well as other oncological diseases such as non-Hodgkin's lymphomas. Additionally, the patent includes intermediate compounds that are useful in the synthesis of the compounds of formula I.
Career Highlights
Hongmao Sun is currently associated with Takeda Pharmaceutical Company Limited, where he continues to contribute to innovative research and development in the pharmaceutical industry. His expertise in chemical compounds has positioned him as a valuable asset in the fight against cancer and other serious diseases.
Collaborations
Some of his notable coworkers include Jianping Cai and Shaoqing Chen, who collaborate with him in various research initiatives at Takeda Pharmaceutical Company Limited.
Conclusion
Hongmao Sun's innovative work in developing PLK1 inhibitor compounds showcases his dedication to improving treatment options for patients with oncological disorders. His contributions to the field of pharmaceuticals are significant and continue to impact medical research positively.